Wandercraft announces a new Series D funding round, bringing total secured financing to $75M to accelerate the creation of a global leader in AI-powered robotics.
The company is building on strong momentum driven by clinical progress, industrial partnerships, and global recognition to expand its leadership in rehabilitation, personal mobility, and humanoid robotics. Through its recent agreement with Renault Group, it is fast-tracking product commercialization and strengthening its position as a global robotics leader.
New York, NY (June 11, 2025) – Wandercraft, a global leader in humanoid robotics, today announced it has secured $75 million in Series D funding, with major contributions from Renault Group, Bpifrance, the European Investment Bank, Teampact Ventures, and Quadrant Management. This financing comes amid rapid growth and international expansion in rehabilitation and personal-use exoskeletons, as well as humanoid robots.
With this capital, Wandercraft is entering a new phase of growth:
– Commercial launch in 2026 of Eve, the world’s first self-balancing personal exoskeleton
– Acceleration of the adoption of its rehabilitation exoskeleton Atalante X in healthcare facilities
– Development and deployment of Calvin-40, its humanoid robot
“The momentum we’ve experienced in recent years has been extraordinary. We’ve expanded internationally, launched our pivotal clinical trial, prepared Eve for commercialization, and established a landmark partnership with Renault Group. This funding enables us to continue our mission: transforming how people live, move, and work — whether in rehab, at home, or soon in factories.”
The announcement follows the strategic partnership between Wandercraft and Renault Group, which now holds a minority stake in the company. This collaboration allows Wandercraft to benefit from Renault’s industrial expertise to scale its exoskeletons and robots, laying the foundation for the industrial rollout of Eve and the Calvin humanoid family.
Renault Group is also the first commercial partner and customer of Wandercraft’s Calvin-40, named after the 40 days it took to develop.
Calvin-40 is an industrial robot designed for physically demanding or strenuous tasks and is the first humanoid robot developed by a European company. It was built in record time thanks to Wandercraft’s rapid development process and cutting-edge robotic platform, integrated with NVIDIA Isaac technology — including the NVIDIA Isaac GR00T N1 foundation model and the NVIDIA Jetson embedded AI platform.
The funds will be deployed over the coming years to:
• Launch Eve, the personal exoskeleton designed for home and urban use
• Scale the next growth phase for Atalante X, the rehabilitation exoskeleton
• Industrialize and deploy Calvin-40 and the broader Calvin humanoid family
“We are delighted to renew our support for Wandercraft, a company backed by Bpifrance since 2017. This Series D, alongside Renault Group, will accelerate the industrial deployment of their globally unique robotic technology and make the Eve exoskeleton accessible to a wide audience. Ensuring access to health and mobility for all is a strategic priority for Bpifrance and the France 2030 plan.”
This news follows Wandercraft’s $45M Series C round in 2022, led by Quadrant Management, which enabled commercial expansion into the U.S. and resulted in a 10x revenue increase over three years.
Other Series D participants include LBO France, Mutuelles Impact – managed by XAnge, Cemag Invest, Martagon Capital, and AG2R LA MONDIALE.
Wandercraft’s momentum is rooted in its mission to restore autonomy for people with mobility impairments using self-balancing exoskeletons that enable natural walking. Enhanced by AI, this technology has been validated in real-world conditions and refined through billions of simulations and tens of millions of real-life steps.
A long list of world firsts, including:
AI-powered clinical innovation
• First FDA clearance for Atalante X in stroke rehab, followed by a second FDA clearance within a year
• Launch of the world’s first clinical trial for a self-balancing personal exoskeleton, Eve, designed to help people with mobility challenges walk hands-free at home and in their communities
• Deployment of Atalante X in over 100 hospitals and rehabilitation centers worldwide, including Kessler Foundation, Villa Beretta Rehabilitation Research Innovation Institute, Vivantes Klinikum Spandau, and Schön Klinik
• Featured in 20+ clinical studies with major results showing improvements in walking speed, balance, independence, and posture — often accompanied by reduced pain, spasticity, and increased muscle strength
• Enabled 2,500 people with mobility impairments to take over 14 million steps to date, rediscovering movement once thought unreachable
Rehabilitation access in the heart of New York
• Opening of Walk in New York by Wandercraft, the first walking center offering regular exoskeleton sessions for people with conditions such as stroke, MS, Parkinson’s, or spinal cord injuries
• Located in Cure®, a New York healthcare innovation campus that also houses Wandercraft’s U.S. HQ
• The center is set to be the regional hub for Eve’s U.S. launch in 2026
Product innovation and recognition
• Eve featured in the 2024 Olympic and Paralympic torch relay, symbolizing a new global standard in mobility tech
• Presented by NVIDIA at CES 2025 and the NVIDIA GTC, the “Super Bowl of AI,” recognizing Wandercraft’s use of NVIDIA’s physical AI platform for autonomous movement
• Winner of the 2025 SXSW Innovation Award in the AI category for its robotic exoskeleton
• Selected for the French Tech 120 index, spotlighting scale-ups set to become global leaders
Wandercraft invites the public to learn more about the ongoing clinical trial for Eve, its personal exoskeleton. The study evaluates real-world usability, focusing on ease of movement, endurance, and day-to-day integration. Adults 18+ with complete or incomplete motor spinal cord injuries (at or above T6) are eligible, provided they have — or are accompanied by — a physically capable assistant. For inquiries or applications, email: clinicaltrials@wandercraft.health
Wandercraft is growing and hiring curious, driven individuals to join the team. If you’re passionate about the future of mobility and solving complex robotics challenges, check out openings in robot control, machine learning, customer service, and software leadership. Bring your expertise and help us build technology that changes the world.
About Wandercraft
Wandercraft is a robotics company on a mission to restore mobility and expand possibilities through AI-powered, self-balancing systems.
Founded in 2012, Wandercraft is globally recognized for creating Atalante X, the world’s first self-balancing walking exoskeleton, now used in over 100 rehabilitation centers across four continents to help individuals with disabilities take over 1 million steps per month.
Building on more than a decade of hands-on experience and a proprietary neural network trained on billions of steps, Wandercraft is extending mobility beyond clinical settings. Its personal exoskeleton, Eve, helps wheelchair users stand and walk in everyday life. With the Calvin family of autonomous humanoid robots, Wandercraft is also expanding into industrial and assistive tasks — relieving workers from dangerous duties and supporting caregivers.
With over 30 patents and a deeply human mission, Wandercraft believes everyone should move freely — and that robotics should meet people where they are, with reliability, responsiveness, and empathy. Learn more at wandercraft.eu.
WANDERCRAFT – PRESS CONTACTS
Lilly Kofler +1 954-292-8187
lilly.kofler@wandercraft.health
Jean-Louis Constanza +33 607 529 895
jean-louis.constanza@wandercraft.health
About Mutuelles Impact
Created in 2020 on the initiative of La Mutualité Française, Mutuelles Impact is the leading mutualist investment fund with a social and environmental impact in the health sector. Its objective is to invest in and develop high-impact companies in the prevention, care pathway, and medico-social sectors. The Mutuelles Impact fund is managed by XAnge, in partnership with Investir&+. With over €95 million, the fund is financed by 63 French mutual health insurers (mutuelles) and 3 territorial players (the Eurométropole de Strasbourg, Banque des Territoires, and e-Meuse santé). It currently has about twenty companies in its portfolio (startups, SMEs, mid-sized companies). More information available at https://www.mutuellesimpact.fr/.
About La Mutualité Française
La Mutualité Française represents nearly 500 mutual health insurers (mutuelles). Born from the desire of men and women to protect themselves collectively against life's uncertainties, mutual health insurers (mutuelles) work for the social protection of 32 million French people and promote the right of all to full health by acting in complementarity and partnership with Social Security (Sécurité Sociale) and by contributing to the public health service.
MASCARET GROUP – PRESS CONTACT
Estelle Monraisse
+33 6 60 41 81 52
estelle@altercom-conseil.fr
